SAVA

Company Overview — What Does CASSAVA SCIENCES INC Do?

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. CASSAVA SCIENCES INC (SAVA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Remi Barbier and employs approximately 30 people, headquartered in AUSTIN, Texas. With a market capitalization of $115M, SAVA is one of the notable companies in the Healthcare sector.

CASSAVA SCIENCES INC (SAVA) Stock Rating — Reduce (April 2026)

As of April 2026, CASSAVA SCIENCES INC receives a Reduce rating with a composite score of 23.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SAVA ranks #3,228 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CASSAVA SCIENCES INC ranks #486 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SAVA Stock Price and 52-Week Range

CASSAVA SCIENCES INC (SAVA) currently trades at $2.38. The stock gained $0.35 (17.2%) in the most recent trading session. The 52-week high for SAVA is $4.98, which means the stock is currently trading -52.2% from its annual peak. The 52-week low is $1.15, putting the stock 107.0% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is SAVA Overvalued or Undervalued? — Valuation Analysis

CASSAVA SCIENCES INC (SAVA) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.55x, versus the sector average of 2.75x.

At current multiples, CASSAVA SCIENCES INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CASSAVA SCIENCES INC Profitability — ROE, Margins, and Quality Score

CASSAVA SCIENCES INC (SAVA) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -143.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -89.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SAVA Debt, Balance Sheet, and Financial Health

CASSAVA SCIENCES INC has a debt-to-equity ratio of 59.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.23x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $106M.

SAVA has a beta of 1.13, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for CASSAVA SCIENCES INC is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CASSAVA SCIENCES INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, CASSAVA SCIENCES INC reported revenue of $0 and earnings per share (EPS) of $-1.88. Net income for the quarter was $-106M. Operating income came in at $-112M.

In FY 2025, CASSAVA SCIENCES INC reported revenue of $0 and earnings per share (EPS) of $-1.88. Net income for the quarter was $-91M. Operating income came in at $-95M.

In Q3 2025, CASSAVA SCIENCES INC reported revenue of $0 and earnings per share (EPS) of $-0.22. Net income for the quarter was $-11M. Operating income came in at $-12M.

In Q2 2025, CASSAVA SCIENCES INC reported revenue of $0 and earnings per share (EPS) of $-0.92. Net income for the quarter was $-44M. Operating income came in at $-45M.

Over the past 8 quarters, CASSAVA SCIENCES INC has experienced revenue contraction from $0 to $0. Investors analyzing SAVA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SAVA Dividend Yield and Income Analysis

CASSAVA SCIENCES INC (SAVA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SAVA Momentum and Technical Analysis Profile

CASSAVA SCIENCES INC (SAVA) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

SAVA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CASSAVA SCIENCES INC (SAVA) ranks #486 out of 838 stocks based on the Blank Capital composite score. This places SAVA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SAVA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SAVA vs S&P 500 (SPY) comparison to assess how CASSAVA SCIENCES INC stacks up against the broader market across all factor dimensions.

SAVA Next Earnings Date

No upcoming earnings date has been announced for CASSAVA SCIENCES INC (SAVA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SAVA? — Investment Thesis Summary

The quantitative profile for CASSAVA SCIENCES INC suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, CASSAVA SCIENCES INC (SAVA) earns a Reduce rating with a composite score of 23.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SAVA stock.

Related Resources for SAVA Investors

Explore more research and tools: SAVA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SAVA head-to-head with peers: SAVA vs AZN, SAVA vs SLGL, SAVA vs VMD.